S. Barry

Biomedical Engineering · Cancer Research · 2005–2017

A researcher in the Science corpus: 3 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom S. Barry trusts

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Rakesh K. Jain (in Biomedical Engineering)

Papers from S. Barry's perspective

Ordered by how strongly the researchers S. Barry trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors (Proceedings of the National Academy of Sciences of the United States of America)
  2. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. (American Journal of Pathology)
  3. VEGF and the quest for tumour angiogenesis factors (Nature Reviews. Cancer)
  4. Lymphatic Metastasis in the Absence of Functional Intratumor Lymphatics (Science)
  5. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. (New England Journal of Medicine)
  6. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1 (Nature Medicine)
  7. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer (Nature Medicine)
  8. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. (Cancer Research)
  9. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins (Nature Immunology)
  10. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. (Cancer Research)

Their papers